|
|
|
|
| LEADER |
02774nam a22003735i 4500 |
| 001 |
000285520 |
| 005 |
20211206084828.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2005 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783540266709
|
| 024 |
7 |
|
|a 10.1007/b137900
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Inhibitors of Protein Kinases and Protein Phosphates /
|c edited by Lorenzo A. Pinna, Patricia T.W. Cohen.
|
| 246 |
3 |
|
|a with contributions by numerous experts
|
| 250 |
|
|
|a 1st ed. 2005.
|
| 260 |
# |
# |
|a Berlin, Heidelberg :
|b Springer Berlin Heidelberg :
|b Imprint: Springer,
|c 2005.
|
| 300 |
|
|
|a X, 458 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of Experimental Pharmacology,
|v 167
|
| 505 |
0 |
|
|a Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems -- General Aspects of PKs Inhibition -- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases -- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 -- Pharmacological Potential of p38 MAPK Inhibitors -- Inhibitors of PKA and Related Protein Kinases -- Inhibitors of Protein Kinase CK2: Structural Aspects -- Aminoglycoside Kinases and Antibiotic Resistance -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases -- Protein Tyrosine Phosphatases as Therapeutic Targets -- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors -- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target -- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity -- Inhibitors in Clinical Use or Advanced Clinical Trials -- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus -- Targeted Therapy with Imatinib: An Exception or a Rule? -- Clinical Aspects of Imatinib Therapy -- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy -- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
|
0 |
|a Pathology.
|
| 650 |
|
0 |
|a Medical biochemistry.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Pathology.
|
| 650 |
2 |
4 |
|a Medical Biochemistry.
|
| 700 |
1 |
|
|a Pinna, Lorenzo A.
|e editor.
|
| 700 |
1 |
|
|a Cohen, Patricia T.W.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|